Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Consensus Rating of “Hold” from Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been given a consensus rating of “Hold” by the five ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.00.

Several analysts have recently weighed in on NBTX shares. Wall Street Zen upgraded Nanobiotix to a “hold” rating in a report on Saturday, October 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Finally, Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. purchased a new stake in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

Nanobiotix Stock Up 1.7%

NBTX opened at $23.04 on Friday. The business’s 50 day moving average is $21.04 and its 200-day moving average is $13.90. Nanobiotix has a twelve month low of $2.82 and a twelve month high of $30.35.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.